Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caltech Uses NTA to Characterize New Therapeutic Nanoparticles

Published: Wednesday, May 01, 2013
Last Updated: Tuesday, April 30, 2013
Bookmark and Share
Caltech to study nanoparticle-based therapeutics for the treatment of dementia, Parkinson's and Alzheimer's diseases.

NanoSight reports on how Nanoparticle Tracking Analysis, NTA, is being applied in the Chemical Engineering Department of the California Institute of Technology to study nanoparticle-based therapeutics being developed for the treatment of illnesses such as dementia and Alzheimer's.

The central theme of the Mark E Davis research group at Caltech is the use of chemical engineering concepts (synthetic chemistry and analytical engineering problem solving) to answer important fundamental questions in the physical and life sciences.

Current research entails designs for the synthesis of inorganic and hybrid, organic-inorganic materials for catalysis and biocompatible materials for the delivery of macromolecular therapeutics.

Dr Devin Wiley is a recent graduate in the Davis Group. His research focuses on delivering nanoparticle therapies across the blood-brain-barrier using targeted nanoparticles.

Pathologies of interest include senior dementia, Parkinson's and Alzheimer's diseases.

The strategy is to deliver large-molecule therapeutics tucked inside nanoparticles that have proteins attached to their surface.

These proteins will bind specifically to receptors on the blood-brain-barrier, allowing the nanoparticles and their therapeutic cargo to be shuttled across the barrier and released into the brain.

To this end, Wiley requires rapid, easy-to-use characterization techniques for the nanoparticles he synthesizes.

Describing his work, Wiley says "We have two main areas of research in our group. One is developing nanoparticle-based therapeutics for the treatment of cancer. The other is designing therapeutics to be delivered to the brain. So far, we have used the NanoSight Nanoparticle Tracking Analysis system to size the nanoparticles we create and then to measure their zeta potentials."

"We selected NTA as it is a convenient and rapid method to size the nanoparticles we have manufactured. Visual confirmation of the nanoparticles is useful. Prior to NTA, we used DLS and a ZetaPALS system from Brookhaven. We would also use CryoTEM to size the nanoparticles. The positive advantage of NTA is its ability to visualize each nanoparticle and then to obtain size distributions based on individual particle measurements. Sizing by NTA is much faster and much cheaper than CryoTEM imaging."

Wiley's work at Caltech has been also showcased as part of TedxCaltech: The Brain.

In a recent presentation, he described this project as a work-around-a way to sneak therapeutics past the barrier and into the brain to potentially treat neurologic diseases: http://tedxcaltech.caltech.edu/content/devin-wiley.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!